Comparative Pharmacology
Head-to-head clinical analysis: SATRIC versus TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SATRIC versus TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE.
SATRIC vs TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
SATRIC is a combination of sulfathiazole, sulfacetamide, and sulfabenzamide, which are sulfonamide antibiotics. They competitively inhibit dihydropteroate synthase, blocking folate synthesis in susceptible bacteria.
Trimethoprim inhibits bacterial dihydrofolate reductase, blocking tetrahydrofolate synthesis and thereby inhibiting thymidine synthesis. Polymyxin B disrupts bacterial cell membrane integrity by binding to lipopolysaccharides in Gram-negative bacteria.
No standard dosing information available for SATRIC.
One drop in each affected eye every 2 to 4 hours for 7 to 10 days.
None Documented
None Documented
3-5 hours in healthy adults; prolonged to 6-8 hours in renal impairment (CrCl < 30 mL/min)
Trimethoprim: 8-10 hours (normal renal function); Polymyxin B: 6 hours (prolonged in renal impairment).
Renal: 70% unchanged; fecal: 20%; biliary: 10%
Trimethoprim: renal (80-90% unchanged, 10-20% metabolites); Polymyxin B: renal (60% unchanged, 40% nonrenal).
Category C
Category D/X
Antiprotozoal, Antibiotic
Antibiotic